Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.70 Average Target Price from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $36.70.

VRDN has been the subject of several analyst reports. The Goldman Sachs Group decreased their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Royal Bank of Canada lowered their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. JMP Securities dropped their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of Viridian Therapeutics in a report on Tuesday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC grew its stake in shares of Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company’s stock worth $2,851,000 after purchasing an additional 66,550 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Viridian Therapeutics by 89.1% in the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company’s stock worth $596,000 after purchasing an additional 14,644 shares in the last quarter. Moody Aldrich Partners LLC bought a new position in shares of Viridian Therapeutics in the fourth quarter worth $1,125,000. Vanguard Group Inc. grew its stake in shares of Viridian Therapeutics by 4.0% in the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company’s stock worth $88,087,000 after purchasing an additional 174,952 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Viridian Therapeutics by 3.3% in the fourth quarter. Principal Financial Group Inc. now owns 178,444 shares of the company’s stock worth $3,421,000 after purchasing an additional 5,634 shares in the last quarter.

Viridian Therapeutics Price Performance

VRDN opened at $13.82 on Friday. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $27.20. The company has a 50 day moving average of $13.29 and a two-hundred day moving average of $17.01. The company has a market cap of $1.13 billion, a P/E ratio of -3.21 and a beta of 0.57. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.16 million. Viridian Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts expect that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.